Associations of peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism with non-alcoholic fatty liver disease: A meta-analysis

Xie, Rong; Tang, Shaobo; Yang, Yugui

doi:10.1016/j.jdiacomp.2022.108261

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is challenging because variants in the Pparγ gene have been linked to metabolic disorders such as atherosclerosis, diabetes, obesity, and NAFLD. In fact, a missense Pro12Ala substitution in the Pparγ2 gene (rs1801282) has been investigated in relation to NAFLD risk in several ethnic groups, and those who carry the Pparγ2 Ala allele polymorphism showed a protective effect against NAFLD [ 160 , 161 ]. Additionally, the SNP rs3856806 (also referred to as C161T or C1431T) in the Pparγ gene increases NAFLD susceptibility through the adiponectin pathway [ 162 , 163 ].…”

Section: Limitations and Future Perspectivesmentioning

confidence: 99%

Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease

Zaiou

2023

Cells

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor-γ (PPARγ) belongs to the superfamily of nuclear receptors that control the transcription of multiple genes. Although it is found in many cells and tissues, PPARγ is mostly expressed in the liver and adipose tissue. Preclinical and clinical studies show that PPARγ targets several genes implicated in various forms of chronic liver disease, including nonalcoholic fatty liver disease (NAFLD). Clinical trials are currently underway to investigate the beneficial effects of PPARγ agonists on NAFLD/nonalcoholic steatohepatitis. Understanding PPARγ regulators may therefore aid in unraveling the mechanisms governing the development and progression of NAFLD. Recent advances in high-throughput biology and genome sequencing have greatly facilitated the identification of epigenetic modifiers, including DNA methylation, histone modifiers, and non-coding RNAs as key factors that regulate PPARγ in NAFLD. In contrast, little is still known about the particular molecular mechanisms underlying the intricate relationships between these events. The paper that follows outlines our current understanding of the crosstalk between PPARγ and epigenetic regulators in NAFLD. Advances in this field are likely to aid in the development of early noninvasive diagnostics and future NAFLD treatment strategies based on PPARγ epigenetic circuit modification.

show abstract

Section: Limitations and Future Perspectivesmentioning

confidence: 99%

Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease

Zaiou

2023

Cells

View full text Add to dashboard Cite

show abstract

Associations of peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism with non-alcoholic fatty liver disease: A meta-analysis

Cited by 1 publication

References 33 publications

Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease

Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About